Inverseon, CBio Combine Programs in All-Stock Merger
Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane.
The merged entity will combine programs from each company to focus broadly on inflammatory disease.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST